About CRAB > Board of Directors
CRAB has assembled a key group of leaders from the non-profit, legal, medical, and statistics fields which comprise our board of directors. These are distinguished supporters of CRAB and its mission.
They are the governing body of CRAB and oversee the organization's activities including financial oversight. The Board of Directors meets a minimum of three times a year to provide helpful insight and guidance for the organization.
Antje Hoering, Ph.D.
John J. Crowley, Ph.D.
David Gray, Ph.D., M.B.A.
Frank X. Curci, J.D.
Gary Goodman, M.D.
Michael LeBlanc, Ph.D.
Patrick Heagerty, Ph.D., M.S.
Roderic Davis, M.B.A.
Steve Snapinn, Ph.D.
Tim Cummins
Since founding CRAB in 1997, Dr. Crowley has served as a sitting member of, and has chaired, the Board of Directors. Dr. Crowley oversees all science conducted at CRAB as well as all research procedures and operations. John was conferred an M.S. and Ph.D. in Biomathematics from the University of Washington and has devoted his career to applying statistics to cancer research.
Please see more information in his biography.
Antje Hoering, Ph.D. is President and Chief Executive Officer of Cancer Research And Biostatistics (CRAB). Dr. Hoering has a distinguished career with CRAB, having joined the organization as a Senior Biostatistician in 2004, transitioning into the role of Chief Scientific Officer in 2013 and taking on the role of Chief Executive Officer in January 2015.
She presently serves as the Principal Investigator for Computing and Data Management for the SWOG Statistics and Data Management Center. She is also the lead statistician for the SWOG Myeloma Committee and an active member of the Myeloma Steering Committee for the National Clinical Trials Network. Dr. Hoering serves as the primary lead statistician of the University of Arkansas for Medical Sciences Myeloma Center. She is also an associate editor of the Statistics in Biopharmaceutical Research journal and co-editor of the third edition of the Handbook of Statistics in Clinical Oncology. Dr. Hoering has led several workshops nationally and internationally on biostatistical principals in oncology clinical trials for a variety of audiences. Dr. Hoering serves as a consultant on a variety of industry sponsored studies, including a Phase III registration trial and has served as the biostatistics representative for Type B and pre-NDA meetings with the FDA. Dr. Hoering holds affiliate appointments at the Fred Hutchinson Cancer Research Center and the Biostatistics Department of the University of Washington.
Before joining CRAB, Dr. Hoering was a senior research associate at the Cancer Center at the Mayo Clinic, and an Assistant Professor at the Mayo Medical School, Rochester, Minnesota. While at the Mayo Clinic she was the lead statistician on several Phase I, II, and III clinical trials in hematological malignancies and breast cancer. She managed a team of statisticians and data analysts in the design, conduct and analysis of these clinical trials.
Dr. Hoering's original training was in Physics. She obtained her BS at the University of Tuebingen, Germany, an MS from Oregon State University, and a PhD from the Max-Planck-Institute for Nuclear Physics in Heidelberg, Germany. She transitioned into biostatistics as an NIH post-doctoral fellow at the Biostatistics Department of the University of Washington. During that time she completed the coursework required for a PhD in Biostatistics, and also performed methods research in the area of HIV vaccine trials at the Fred Hutchinson Cancer Research Center. She is also a graduate of the Executive Development Program at the Foster Business School at the University of Washington.
Please see more information in her biography.
Angie Schroeder is the Director of Program Operations for the Biostatistics, Bioinformatics and Epidemiology Program at Fred Hutch. Ms. Schroeder has over 20 years of experience in the life science industry in both the non-profit and for-profit sectors. Prior to Fred Hutch, Ms. Schroeder held management roles at Corixa Corp. (acquired by GSK), CTI Biopharm Corp., Dendreon Corp. and the Infectious Disease Research Institute, focused on operations, finance and strategic analysis. Ms. Schroeder received her B.A. and M.B.A. from the University of Washington.
Cynthia Adkins brings over twenty-two years of legal experience to the CRAB Board of Directors.
As a founder and managing member of Adkins, Plant, Elvins & Black, a life sciences law firm that serves the biotechnology, pharmaceutical and medical device industries, Cynthia Adkins provides legal solutions for the life sciences by focusing primarily on international and domestic clinical trials and research and manufacturing transactions, and negotiating with sites and companies in the United States, Europe, Russia, Asia and South America. Ms. Adkins travels extensively to support her clients’ international requirements, and she has established a strong network of international life sciences counsel to assist with local law issues.
Before co-founding her own firm, she served as senior counsel for Immunex Corporation, where she negotiated biotechnology manufacturing agreements, clinical trial agreements, supply agreements, software licenses and internet hosting agreements. She was the recipient of the company’s “Applause Award” for her timely divestiture of four oncology products. Throughout her extensive legal career, Cynthia also served as senior counsel at HomeGrocer.com, counsel and Vice-President at Washington Mutual Bank, and counsel to the treasury group at Boeing.
Cynthia holds a BA from Washington State University and a Juris Doctorate from the University of Washington.
David Gray is a consultant who works with companies and organizations pursuing oncology research and drug development from translation through regulatory approval and marketing. He has been involved in clinical drug development in the pharmaceutical and biotechnology industries for over twenty-five years and feels fortunate to have participated in the development of several life changing therapies including a targeted antibody drug conjugate for Hodgkin and T-cell lymphomas. In addition to serving on the Board of Directors of CRAB he also serves on the Board of GRACE, Global Resource for Advancing Cancer Education. He has an MBA from the Wharton School at the University of Pennsylvania and a PhD in Statistics from the University of Kentucky.
Frank X. Curci is an intellectual property and technology attorney and a shareholder at Buchalter Ater Wynne. Frank represents clients regarding their intellectual property, research and technology matters, including patent/technology licensing, technology collaborations, research issues, technology transfers, and the overall development, protection, commercialization, and use of intellectual property rights. Mr. Curci’s clients include bioscience and high-technology companies, research universities, other bioscience research institutions, and technology accelerator entities. Frank is active with bioscience and high tech industry associations, including the Oregon Bioscience Association and, previously, the Arizona BioIndustry Association. For several years he has been an Adjunct Professor of Law teaching intellectual property law courses at Oregon, California and Arizona law schools and currently teaches at Lewis & Clark Law School in Portland, OR.
The interests of Dr. Goodman dovetail uniquely with those of CRAB. He is an oncologist at Swedish Hospital in Seattle and also holds a joint membership with the Fred Hutchinson Cancer Research Center. He has held prominent positions in SWOG, the most pertinent to CRAB is his Chairmanship of the Chemoprevention Committee. He was the Principal Investigator (PI) of the Carotene and Retinol Efficacy Trial (CARET) and Principal Investigator at Swedish for SWOG’s Selenium and Vitamin E Cancer Prevention Trial (SELECT).
Dr. Goodman has been an advisor to the SWOG H Pylori Project in South and Central America. The latter two, massive projects have both been coordinated by the Statistical Center of SWOG at CRAB.
Dr. Goodman has been a long-time supporter of CRAB, serving on its IRB for 10 years.
Dr. Goodman received his M.D. and M.S. in Pharmacology from the University of Illinois in 1974.
Dr. Heagerty is Professor and Chair of the Department of Biostatistics at the University of Washington, and Gilbert S. Omenn Endowed Chair in Biostatistics. He received a PhD from the Johns Hopkins University, and a BS from Cornell University. He has extensive experience as an educator, independent and collaborative scientist, and administrator.
Dr. Heagerty has developed fundamental methods for longitudinal studies with a focus on prognostic model evaluation and structural longitudinal models, and he has detailed methods for the design, analysis, and interpretation of cluster-randomized trials conducted within health care delivery systems. Dr. Heagerty has co-authored two leading textbooks (Analysis of Longitudinal Data, Oxford 2002; Biostatistics: A Methodology for the Health Sciences, Wiley 2004).
Dr. Heagerty is an elected Fellow of the American Statistical Association, and has twice been honored by professional societies for specific research contributions (in 2000 as the Snedecor Award winner; and in 2005 by the International Biometrics Society for the best paper published in the society’s flagship journal, Biometrics). Dr. Heagerty directs the Center for Biomedical Statistics (CBS), a core partially funded by the NIH Clinical and Translational Science Award (CTSA) with responsibility for coordination of biostatistical collaboration in Seattle and the greater Northwest region (Wyoming, Alaska, Idaho, Montana). The CBS houses the data coordinating centers for several U01 and R01 funded projects including GARNET (Genomics and Randomized Trials), BOLD (Backpain Outcomes using Longitudinal Data), UH3 funded pragmatic trials including LIRE (Lumbar Imaging Reporting with Epidemiology), and PCORI funded trials. The CBS has previously conducted high-impact multi-site randomized trials including INVEST (Investigational Vertebroplasty Safety and Efficacy Trial, NEJM 2009), the Carpal Tunnel Surgical Trial (Lancet 2009), and LESS (Lumbar Epidural Steroid Injections for Spinal Stenosis, NEJM 2014).
Dr. Heagerty is also a licensed teacher (NY State: Mathematics, Biology, and Chemistry) and has taught from middle school to graduate school (UW SPH Outstanding Teacher Award, 2009).
John previously worked for Fidelity Investments, in Boston, and with Morgan Stanley. He earned his Bachelor’s Degree in communication at the University of Colorado. He has lived in Seattle since 2004, and for the past three years has served on the board for Band of Brothers NW, a nonprofit that helps families of terminally ill children. Additionally, in John’s free time, he enjoys playing golf, skiing and riding motorcycles as well as spending time with his wife Hillary and their 8 year old boxer Cassius.
Roderic Davis is a Relationship Manager and Loan Officer at the Commerce Bank of Washington in Seattle. He works with a wide variety of clients including businesses, commercial real estate owners and private banking clients. Roderic has been in the financial services industry for over twenty-three years; the past 12 at Commerce Bank and the prior 11+ at Bank of Scotland. His financial interest was piqued while earning his BA in Economics at the University of Washington and then continued while earning his MBA at Loyola University of Chicago. After completing university he went on to complete the Chartered Financial Analyst program and earned the CFA designation. The combination of his propensity to “do the math" and analyze numbers combined with several instances of loved ones having cancer have led to his interest in serving & supporting CRAB.
Dr. LeBlanc is a full member of the Fred Hutchinson Cancer Research Center, a Research Professor of Biostatistics at the University of Washington and both the current Group Statistician and Principal Investigator of the SWOG Statistics and Data Management Center Grant (U10 CA180819). He brings extensive experience in the design and analysis of clinical trials and also a significant personal research record both in clinical trials and adaptive regression methods relevant to the analysis of clinical trials and cohort data.
Dr. LeBlanc’s collaborative research focuses on statistical activities related to Phase II and Phase III clinical trials. His research interests include the design and analysis of clinical trials, methods for exploratory analysis of survival data and adaptive non-parametric regression. Most of his collaborative research focuses on the design, analysis and conduct of therapeutic clinical trials. Dr. LeBlanc was named a 2019 Fellow of the American Statistical Association. He holds a PhD from the University of Washington and a Masters in Mathematics from the University of Waterloo.
Steven Snapinn has had a long career as a biostatistician in the pharmaceutical industry, including 20 years at Merck in Pennsylvania and 15 years leading the biostatistics organization at Amgen in Thousand Oaks, California. He is currently an independent consultant at Seattle-Quilcene Biostatistics LLC and living in Seattle. During his career he led the biostatistical efforts for more than a dozen successful pharmaceutical products in multiple therapeutic area. He has over 100 publications in the statistical and medical literature, has been honored fellow of the American Statistical Association, and has served as editor of the journal Statistics in Biopharmaceutical Research.
Tim Cummins founded Sonata Capital Group in Seattle in 2000. He is the Chief Investment Officer focusing on investment solutions for individuals, smaller endowments and multi-generational trust & estate management. Tim has been in the financial services industry for over thirty years, with previous experience as an equity trader for Westpac PLC in New York, Portfolio Manager for Key Bank & lead manager for Rigel Capital Management’s growth and technology funds. His first passion was studying history for 4 years before discovering his analytical & research skills & ability to (think in) numbers working as an equity trader for Westpac Bank PLC in New York. After obtaining his financial accreditations in New York, he earned his BA in Finance from Seattle Pacific University. His enjoyment, especially analyzing Biotech Companies as well as a respect for science and statistics give him a particular interest in serving & supporting CRAB.